Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment

被引：2
|
作者：
Provencio, M.
Cobo, M.
Vazquez-Estevez, S.
Firvida, J.
Macia, S.
Barneto, I.
Oramas, J.
Sanchez-Hernandez, A.
Ferrer, N.
Paredes, A.
机构：
[1] Hosp Puerta de Hierro, Madrid, Spain
[2] Hosp Univ Carlos Haya, Malaga, Spain
[3] Complexo Xeral Calde, Lugo, Spain
[4] Complexo Hosp Ourense, Orense, Spain
[5] Hosp Gen Elda, Elda, Spain
[6] Hosp Univ Reina Sofia, Dept Clin Oncol, Cordoba, Spain
[7] Hosp Univ Canarias, Santa Cruz De Tenerife, Spain
[8] Hosp Prov Castellon, Castellon de La Plana, Spain
[9] Hosp Son Llatzer, Palma De Mallorca, Spain
[10] Hosp Donostia, San Sebastian, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18109
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18109
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Ardizzoni, A
    Tiseo, M
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 104 - 107
  • [2] Weekly docetaxel as a second-line treatment for advanced non-small cell lung cancer (NSCLC).
    García, R
    Pérez, P
    Alfonso, R
    Pérez-Manga, G
    Díaz-Rubio, E
    ANNALS OF ONCOLOGY, 2000, 11 : 116 - 116
  • [3] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
  • [4] Second-line treatment options in advanced non-small cell lung cancer
    de Marinis, Filippo
    Ricciardi, Serena
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S258 - S271
  • [5] Histologic review of second-line permetrexed treatment in patients with non-small cell lung cancer (NSCLC)
    Virani, S.
    Almubarak, M.
    Rogers, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Pemetrexed as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): Efficacy and correlation with molecular markers
    Blasco, A.
    Sirera, R.
    Terrasa, J.
    Provencio, M.
    Guillen, C.
    Maestu, I.
    de las Penas, R.
    Bover, I.
    Berdiel, M.
    de Aguirre, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Second-line treatment with Gemcitabine and Vinorelbine in non-small cell lung cancer (NSCLC): A retrospective analysis of 46 patients
    Czerny, P
    Treutler, D
    Schneider, CP
    Bonnet, R
    8TH CENTRAL EUROPEAN LUNG CANCER CONFERENCE, 2002, : 275 - 278
  • [8] SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
    Cullen, M.
    LUNG CANCER, 2009, 64 : S13 - S13
  • [9] Advanced non-small cell lung cancer. Maintenance and second-line treatment
    Schuette, W.
    Nagel, S.
    Haak, G.
    Steinert, M.
    PNEUMOLOGE, 2012, 9 (01): : 43 - 48
  • [10] Docetaxel and mitomycin as second-line treatment in advanced non-small cell lung cancer
    J. Feliu
    G. Martín
    J. Castro
    A. Sundlov
    A. Rodriguez-Jaráiz
    E. Casado
    M. Lomas
    C. Madroñal
    A. Galán
    C. Belda
    M. Gonzalez-Barón
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 527 - 531
12345